JP2002506830A - 治療的ケモカイン受容体アンタゴニスト - Google Patents

治療的ケモカイン受容体アンタゴニスト

Info

Publication number
JP2002506830A
JP2002506830A JP2000536397A JP2000536397A JP2002506830A JP 2002506830 A JP2002506830 A JP 2002506830A JP 2000536397 A JP2000536397 A JP 2000536397A JP 2000536397 A JP2000536397 A JP 2000536397A JP 2002506830 A JP2002506830 A JP 2002506830A
Authority
JP
Japan
Prior art keywords
cxcr4 antagonist
sdf
cells
cxcr4
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000536397A
Other languages
English (en)
Japanese (ja)
Inventor
イアン クラーク−ルイス
ジャン−ホン ゴン
ビンセント デュロニオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002226391A external-priority patent/CA2226391A1/en
Priority claimed from CA002245224A external-priority patent/CA2245224A1/en
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of JP2002506830A publication Critical patent/JP2002506830A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
JP2000536397A 1998-03-13 1999-03-12 治療的ケモカイン受容体アンタゴニスト Pending JP2002506830A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA002226391A CA2226391A1 (en) 1998-03-13 1998-03-13 N-terminal peptides of sdf-1 have functional activities mediated by cxcr4
CA2,226,391 1998-03-13
CA002245224A CA2245224A1 (en) 1998-08-14 1998-08-14 Chemokine receptor antagonists and chemotherapeutics
CA2,245,224 1998-08-14
PCT/CA1999/000221 WO1999047158A2 (en) 1998-03-13 1999-03-12 Therapeutic chemokine receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009242544A Division JP2010047598A (ja) 1998-03-13 2009-10-21 治療的ケモカイン受容体アンタゴニスト

Publications (1)

Publication Number Publication Date
JP2002506830A true JP2002506830A (ja) 2002-03-05

Family

ID=25679974

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000536397A Pending JP2002506830A (ja) 1998-03-13 1999-03-12 治療的ケモカイン受容体アンタゴニスト
JP2009242544A Pending JP2010047598A (ja) 1998-03-13 2009-10-21 治療的ケモカイン受容体アンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009242544A Pending JP2010047598A (ja) 1998-03-13 2009-10-21 治療的ケモカイン受容体アンタゴニスト

Country Status (7)

Country Link
US (2) US6946445B1 (de)
EP (1) EP1061944B1 (de)
JP (2) JP2002506830A (de)
AT (1) ATE258444T1 (de)
AU (1) AU762472B2 (de)
DE (1) DE69914463T2 (de)
WO (1) WO1999047158A2 (de)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004107333A (ja) * 2002-08-27 2004-04-08 Takeda Chem Ind Ltd Ｃｘｃｒ４拮抗薬およびその用途
JP2009526861A (ja) * 2006-02-14 2009-07-23 ゲイシンガー クリニック 血管新生標的としてのｇｐｃｒ
JP2009531283A (ja) * 2006-02-02 2009-09-03 アラーガン、インコーポレイテッド 眼系疾患の処置のための組成物および方法
US8410059B2 (en) 2002-08-27 2013-04-02 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US8455450B2 (en) 2006-12-21 2013-06-04 Biokine Therapeutics Ltd. Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
JP2017508005A (ja) * 2014-02-19 2017-03-23 マイクロコンスタンツ チャイナ インク ケモカイン受容体アンタゴニストおよびその併用療法
JP2019528241A (ja) * 2016-06-16 2019-10-10 サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィクＣｅｎｔｒｅ Ｎａｔｉｏｎａｌ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｓｃｉｅｎｔｉｆｉｑｕｅ インターフェロンレベルを低下させるのに有用な化合物
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
JP2020533406A (ja) * 2017-09-18 2020-11-19 ティーシーエム バイオテック インターナショナル コーポレーション 癌を治療するための治療用の組み合わせおよび方法
US10993985B2 (en) 2016-02-23 2021-05-04 BioLmeRx Ltd. Methods of treating acute myeloid leukemia

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US20080318855A1 (en) * 1998-03-13 2008-12-25 Chemokine Corporation Dna encoding for recombinant polypeptide emutants of human stromal cell-derived factor 1
DE69914463T2 (de) 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
AU766675B2 (en) * 1998-03-30 2003-10-23 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
US6863887B1 (en) 1998-03-30 2005-03-08 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6949243B1 (en) 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
EP1323730B1 (de) 2000-09-05 2010-04-21 Biokine Therapeutics Ltd. Neue polypeptide und anti-hiv-arzneimittel, die diese enthalten
WO2002022657A2 (en) * 2000-09-12 2002-03-21 University Of British Columbia Peptide antagonist of multiple chemokine receptors and uses thereof
US7253007B2 (en) 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
EP1503786A2 (de) 2002-05-10 2005-02-09 IPF Pharmaceuticals GmbH Methode zur hemmung der emigration von zellen aus dem intravaskulären kompartiment ins gewebe
DE10240064A1 (de) * 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
US7358044B2 (en) * 2003-04-16 2008-04-15 Argyll Biotechnologies, Llc. Prophylactic and therapeutic benefits of a new class of immune stimulating peptides
WO2004094465A2 (en) * 2003-04-23 2004-11-04 The Board Of Trustees Of The University Of Illinois Office Of Technology Management University Of Illinois At Urbana-Champaign Synthetic molecules that mimic chemokines
AU2005209921B2 (en) * 2004-02-03 2011-04-07 Chemocentryx, Inc. Methods and compositions for modulating angiogenesis
US8008312B2 (en) 2005-01-07 2011-08-30 Emory University CXCR4 antagonists for the treatment of HIV infection
EP1898943B1 (de) 2005-05-25 2012-10-10 Hadasit Medical Research Services & Development Ltd. Cxcr4-antagonisten für wundheilung und reepithelialisierung
UA96926C2 (ru) * 2005-10-31 2011-12-26 Мерк Сероно Са Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
WO2008008854A2 (en) 2006-07-11 2008-01-17 Emory University Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US20110044945A1 (en) * 2007-02-08 2011-02-24 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
WO2008109076A1 (en) * 2007-03-02 2008-09-12 Oxigene, Inc. Methods for enhancing the efficacy of vascular disrupting agents
GB0716897D0 (en) * 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
EP2237798A2 (de) 2007-12-12 2010-10-13 Imperial Innovations Limited Verfahren
AU2009228034A1 (en) 2008-03-28 2009-10-01 Altiris Therapeutics Chemokine receptor modulators
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
JP5522072B2 (ja) 2010-03-04 2014-06-18 株式会社デンソー 車両用通信装置および車両用通信システム
US20130303460A1 (en) * 2011-01-10 2013-11-14 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
BR112013029482A2 (pt) 2011-05-16 2016-08-09 Genzyme Corp utilização de antagonistas cxr4
EP2717894B1 (de) 2011-06-07 2018-01-24 Mesoblast International Sàrl Verfahren zur reparatur von gewebeschäden mithilfe proteaseresistenter mutanten des stromazellenfaktors 1
PL224854B1 (pl) * 2013-08-23 2017-02-28 Univ Warszawski Nowy peptydomimetyk o aktywności antyangiogennej i zawierająca go kompozycja farmaceutyczna
WO2015031722A1 (en) 2013-08-30 2015-03-05 Ramot At Tel-Aviv University Ltd. Method for treating amyotrophic lateral sclerosis by inhibition of cxcr4/cxcl12 signaling
US20170042893A1 (en) 2014-02-03 2017-02-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of casein kinase i inhibitors for depleting stem cells
CN108009443A (zh) * 2017-11-30 2018-05-08 广州天鹏计算机科技有限公司 数据的访问方法和***

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2760992A (en) 1956-08-28 Naphthalene
US2530369A (en) 1948-01-29 1950-11-21 Phillips Petroleum Co Oxidation of aromatic compounds
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
JP2703893B2 (ja) * 1985-07-05 1998-01-26 ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ 外来遺伝子物質を発現する上皮細胞
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
JP3015383B2 (ja) 1987-09-11 2000-03-06 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 形質導入した線維芽およびそれらの使用
US4890286A (en) * 1987-12-11 1989-12-26 Sanyo Electric Co., Ltd. Method and apparatus for decoding error correcting code
DE3851153T2 (de) 1987-12-11 1995-01-05 Hughes Howard Med Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ATE124421T1 (de) 1989-09-25 1995-07-15 Genetics Inst Verfahren zur wachstumshemmung von stammzellen.
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
US5401651A (en) * 1991-10-16 1995-03-28 Walz; Alfred DNA encoding ENA-78, a neutrophil activating factor
ES2126606T3 (es) 1991-11-15 1999-04-01 Univ California Terapia del sistema nervioso central mediante celulas modificadas geneticamente.
JPH07502404A (ja) 1991-12-23 1995-03-16 ブリティッシュ　バイオ−テクノロジー　リミテッド 幹細胞阻害タンパク質
RU2155066C2 (ru) 1993-03-31 2000-08-27 Про-Ньюрон, Инк. Ингибитор пролиферации стволовых клеток и его использование
AU7568094A (en) 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
EP0721503A1 (de) 1993-09-28 1996-07-17 The General Hospital Corporation Gebrauch von "antisense"-oligonukleotiden zur modulierung des nerven-wachstums und zum umkehren von beta/a4-induzierte morphologie
JP3367581B2 (ja) * 1993-10-14 2003-01-14 小野薬品工業株式会社 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
WO1995019436A1 (en) 1994-01-13 1995-07-20 The Regents Of The University Of California Mammalian monocyte chemoattractant protein receptors
DE69526395D1 (de) 1994-08-13 2002-05-23 Roche Diagnostics Gmbh Verwendung von Interferon-gamma zur Vermeidung der Proliferation und Differenzierung der primitiven Hämapoietischen Vorläuferzellen
US5990163A (en) 1995-01-13 1999-11-23 The Salk Institute For Biological Studies Selective modulation of processes mediated by retinoid X receptors, and compounds useful therefor
US6221361B1 (en) 1995-01-19 2001-04-24 Syntro Corporation Recombinant swinepox virus
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
JPH09206071A (ja) 1996-01-29 1997-08-12 Novo Nordisk As バクテリア由来の酸化酵素
WO1997028258A1 (en) * 1996-01-30 1997-08-07 The National Institutes Of Health Cells expressing both human cd4 and cxcr4
JP2000514049A (ja) 1996-06-27 2000-10-24 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８受容体拮抗薬
US6046185A (en) 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
FR2751658B1 (fr) * 1996-07-26 1998-10-02 Pasteur Institut Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih
AR008290A1 (es) 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
WO1998009642A2 (en) * 1996-09-06 1998-03-12 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Therapeutic chemokine antagonists
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
IT1291353B1 (it) * 1997-05-12 1999-01-07 San Raffaele Centro Fond Peptidi con attivita' antivirale
US6136827A (en) 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6013644A (en) 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
DE69914463T2 (de) 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO2000059928A1 (en) * 1999-04-07 2000-10-12 Thomas Jefferson University Chemokine-derived synthetic peptides
JP2002543126A (ja) 1999-05-03 2002-12-17 スミスクライン・ビーチャム・コーポレイション Ｃｘｃｒ−４受容体アンタゴニスト−トロンボポエチン模倣物
US6356887B1 (en) * 1999-06-28 2002-03-12 Microsoft Corporation Auto-parameterization of database queries
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US7091310B2 (en) 2002-09-13 2006-08-15 Chemokine Therapeutics Corporation Chemokine analogs for the treatment of human disease
CA2335109A1 (en) 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
US6639134B2 (en) * 2000-10-03 2003-10-28 Eric T. Schmidt High flow stringed instrument sound hole
US20030202963A1 (en) * 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
US20030004136A1 (en) * 2001-03-05 2003-01-02 Geeta Saxena IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
US6515001B2 (en) * 2001-03-05 2003-02-04 Chemokine Therapeutic Corporation IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
US6693134B2 (en) * 2001-05-29 2004-02-17 Chemokine Therapeutics Corporation Bicyclic aromatic chemokine receptor ligands
US6831101B2 (en) * 2001-06-14 2004-12-14 Chemokine Therapeutics Corporation Tricyclic rantes receptor ligands
US20030092674A1 (en) * 2001-06-14 2003-05-15 Geeta Saxena Tricyclic rantes receptor ligands

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
JP2004107333A (ja) * 2002-08-27 2004-04-08 Takeda Chem Ind Ltd Ｃｘｃｒ４拮抗薬およびその用途
US8410059B2 (en) 2002-08-27 2013-04-02 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
JP2009531283A (ja) * 2006-02-02 2009-09-03 アラーガン、インコーポレイテッド 眼系疾患の処置のための組成物および方法
JP2009526861A (ja) * 2006-02-14 2009-07-23 ゲイシンガー クリニック 血管新生標的としてのｇｐｃｒ
US8455450B2 (en) 2006-12-21 2013-06-04 Biokine Therapeutics Ltd. Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
US8663651B2 (en) 2006-12-21 2014-03-04 Biokine Therapeutics Ltd. T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation
US8765683B2 (en) 2006-12-21 2014-07-01 Biokine Therapeutics Ltd. T-140 peptide analogs having CXCR4 super-agonist activity for cancer therapy
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
JP2017508005A (ja) * 2014-02-19 2017-03-23 マイクロコンスタンツ チャイナ インク ケモカイン受容体アンタゴニストおよびその併用療法
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11607444B2 (en) 2015-07-16 2023-03-21 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
US11648293B2 (en) 2015-07-16 2023-05-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11642393B2 (en) 2015-07-16 2023-05-09 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11534478B2 (en) 2015-07-16 2022-12-27 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11554159B2 (en) 2015-07-16 2023-01-17 Blokine Therapeutics Ltd. Compositions and methods for treating cancer
US11559562B2 (en) 2015-07-16 2023-01-24 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11590200B2 (en) 2015-07-16 2023-02-28 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11596666B2 (en) 2015-07-16 2023-03-07 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11638742B2 (en) 2015-07-16 2023-05-02 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11612638B2 (en) 2015-07-16 2023-03-28 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11638743B2 (en) 2015-07-16 2023-05-02 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US10993985B2 (en) 2016-02-23 2021-05-04 BioLmeRx Ltd. Methods of treating acute myeloid leukemia
JP2019528241A (ja) * 2016-06-16 2019-10-10 サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィクＣｅｎｔｒｅ Ｎａｔｉｏｎａｌ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｓｃｉｅｎｔｉｆｉｑｕｅ インターフェロンレベルを低下させるのに有用な化合物
JP2020533406A (ja) * 2017-09-18 2020-11-19 ティーシーエム バイオテック インターナショナル コーポレーション 癌を治療するための治療用の組み合わせおよび方法

Also Published As

Publication number Publication date
US7423011B2 (en) 2008-09-09
EP1061944A2 (de) 2000-12-27
AU2821699A (en) 1999-10-11
ATE258444T1 (de) 2004-02-15
DE69914463D1 (en) 2004-03-04
JP2010047598A (ja) 2010-03-04
WO1999047158A3 (en) 1999-11-25
WO1999047158A2 (en) 1999-09-23
AU762472B2 (en) 2003-06-26
DE69914463T2 (de) 2004-11-11
US6946445B1 (en) 2005-09-20
US20050265969A1 (en) 2005-12-01
EP1061944B1 (de) 2004-01-28

Similar Documents

Publication Publication Date Title
JP2002506830A (ja) 治療的ケモカイン受容体アンタゴニスト
US6875738B1 (en) Therapeutic chemokine receptor antagonists
EP1286684B1 (de) Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
WO2000009152A1 (en) Therapeutic chemokine receptor antagonists
US7435718B2 (en) CXCR4 antagonist treatment of hematopoietic cells
Brunner et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow‐derived progenitor cells via the CXCR‐4/SDF‐1 axis
AU2001258110A1 (en) Cxcr4 antagonist treatment of hematopoietic cells
EP1276493B1 (de) Behandlung von hematopoietischen zellen mit cxcr4 agonisten
US7378098B2 (en) CXC chemokine receptor 4 agonist peptides
AU2001252081A1 (en) CXCR4 Agonist Treatment of Hematopoietic Cells
WO2003037376A1 (fr) Prophylactiques et/ou remedes pour le traitement de l'arteriosclerose apres transplantation dans le cas de rejet de greffe
CA2322764A1 (en) Therapeutic chemokine receptor antagonists
AU2005201244B2 (en) CXCR4 agonist treatment of hematopoietic cells
CA2305036A1 (en) Cxcr4 agonist treatment of hematopoietc cells
CA2405907A1 (en) Cxcr4 agonist treatment of hematopoietic cells
CA2408319A1 (en) Cxcr4 antagonist treatment of hematopoietic cells

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060209

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090721

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091210

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100525